
LAVA Therapeutics NV
NASDAQ:LVTX

Gross Margin
LAVA Therapeutics NV
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | Company | Market Cap |
Gross Margin |
||
---|---|---|---|---|---|
NL |
![]() |
LAVA Therapeutics NV
NASDAQ:LVTX
|
30m USD |
98%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
0%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
329.3B USD |
70%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
155.5B USD |
62%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
131.5B USD |
78%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.9B USD |
86%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
76%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
119.5B AUD |
52%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
62.8B USD |
87%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
75%
|
|
NL |
![]() |
argenx SE
XBRU:ARGX
|
29.8B EUR |
90%
|
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on LAVA Therapeutics NV's most recent financial statements, the company has Gross Margin of 97.9%.